Favorite      Chinese 
Home        /        About us         /         Product         /         Srles         /         News         /         Down Message    |    Contact
 
 
 
 News
Company Notice
Medicine News
You are in: home > news   
 
CT guided radioactive 125I seed implantation compared with first-line chemotherapy in treating localized advanced pulmonary carcinoma: a control study
2008-11-5 10:54:35
 
[Abstract] Objective To investigate the clinical value of CT guided radioactive seed 125I implantation(CTRISI) in the treatment of localized advanced pulmonary carcinoma. Methods Thirty-two patients (Group A) with localized advanced pulmonary carcinoma, received radioactive seed 125I  implantation after failure in first line chemotherapy. There were 15 males, and 17 females, ageing from 31 to 73 years old, 52.0 on the average. There were 48 lesions in the 32 patients altogether and all the lesions had a clear border with the adjacent normal tissue. The diameter of tumors was 4.5-7.5cm , the average was 5.5cm. All the cases had been confirmed as malignant by pathology (percutaneous aspiration biopsy). 125I seeds of 2.2~3.3×10megabecquerel(MBq)were implanted into these lesions. The total number of the seeds implanted in each lesion was 10~100. The dosage of the region around the tumor was 100~150Gy. According to Treatment Planning System (TPS), we implant the 125I seeds into the tumors under CT guidance . We picked 30 patients (Group B) to be treated by first line chemotherapy in our hospital randomly as the control group. Results The results of CT follow-up after two months proved that the local control rate of the group treated with 125I seeds implantation was 78.1%, one year survival rate was 65.0%, median survival time was 15 months. Small amount of effusion was observed in these patients during operation. Pneumothorax happened in 4 cases with one of the lungs compressed less than 30 percent and got improved healthy after conservative treatment. One week after the procedure, bloody sputum occured in 15 cases. No medullary suppression and other serious complications occurred in these patients. The local control rate of the control group was 43.3%, one year survival rate was 48.0%, median survival time was 11 months, the incidence rate of medullary suppression is 46.3%. There was a significant difference between the two groups. Conclusion CTGRISI procedure is safe and well-tolerated in treating localized advanced pulmonary carcinoma in Chinese patients with few complications; it can improve the living quality obviously and has good short-term effects.
Key words】Iodine radioisotopes; interventional; brachytherapy; localized advanced stage pulmonary carcinoma; evaluation studies
 
企业简介   /   产品世界   /   临床指导   /   市场营销   /   新闻中心   /   下载中心 www.jacopharm.com
版权所有 pc28_pc28_君安药业 全国免费电话:800-801-2600 手机用户请拨打:400-601-2600 86-0574-26882516 电话:0574-86230301 86230302 传真:0574-86227232 86228695 地址:浙江省宁波市北仑区义成路28号 邮编:315803 E-mail:junan@jacopharm.com ICP备案序号:浙ICP备06002142